Product
E10030 plus Lucentis
1 clinical trial
1 indication
Indication
Age-related macular degenerationClinical trial
A Phase 2, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination With Lucentis in Subjects With Neovascular Age-Related Macular DegenerationStatus: Completed, Estimated PCD: 2012-06-01